At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 65 enrolled
Drug / intervention
AZD4818 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4-week Double-blind, Placebo-controlled, Randomized, Parallel Group Phase IIa Study to Assess the Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
In Brief
A Phase 2 clinical trial evaluating AZD4818 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 65 participants across 12 sites in 5 countries.
Detailed Summary
The purpose of this study is to see if treatment with AZD4818 for four weeks is tolerable, safe and effective in treating COPD and, if so, how it compares with placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesDenmark, Finland, Netherlands, Norway, Sweden
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedMar 2008
Primary CompletionJun 2008
Study CompletionAug 2008
TodayJul 2026
First PostedMar 5, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2008
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.3 years ago
Interventions
AZD4818drug
Dry Powder, inhalation, b.i.d., 4 weeks
Placebodrug